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ABSTRACT Structure-function studies of the Cys loop family of ionotropic neurotransmitter receptors (GABA, nACh, 5-HT3,
and glycine receptors) have resulted in a six-loop (A–F) model of the agonist-binding site. Key amino acids have been identiﬁed
in these loops that associate with, and stabilize, bound ligand. The next step is to identify the structural rearrangements that
couple agonist binding to channel opening. Loop F has been proposed to move upon receptor activation, although it is not known
whether this movement is along the conformational pathway for channel opening. We test this hypothesis in the GABA receptor
using simultaneous electrophysiology and site-directed ﬂuorescence spectroscopy. The latter method reveals structural
rearrangements by reporting changes in hydrophobicity around an environmentally sensitive ﬂuorophore attached to deﬁned
positions of loop F. Using a series of ligands that span the range from full activation to full antagonism, we show there is no
correlation between the rearrangements in loop F and channel opening. Based on these data and agonist docking simulations
into a structural model of the GABA binding site, we propose that loop F is not along the pathway for channel opening, but rather
is a component of the structural machinery that locks ligand into the agonist-binding site.INTRODUCTION
g-Aminobutyric acid (GABA) is the main inhibitory neuro-
transmitter in the mammalian central nervous system (1).
The binding of GABA to its pentameric receptor on the post-
synaptic membrane leads to the opening of an integral chlo-
ride pore that typically hyperpolarizes the neuron (in adults),
thereby reducing excitability. The GABA receptor is a target
for a variety of substances that can modulate its activity,
including benzodiazepines, barbiturates, neurosteroids, anes-
thetics, and alcohol (2). Several decades of research have
revealed insights into the mechanisms and structures that
underlie GABA receptor activation, modulation, regulation,
and permeation (3).
Fig. 1 A shows a structural model of the pentameric r1
GABA receptor determined via homology modeling from
the acetylcholine-binding protein (AChBP). The original
report of the AChBP structure confirmed the presence of
six loops (A–F; colored in Fig. 1 A) at each subunit interface
that form the agonist-binding site (4). Loops A–C are
contributed by one subunit, and loops D–F are contributed
by the neighboring subunit. For the pentameric GABAA re-
ceptor comprised of the prototypical a, b, and g subunits
with a 2:2:1 stoichiometry (5,6), there are two agonist-bind-
ing sites. For the homomeric GABAC receptor comprised of
the five r1 subunits studied here, there are five putative bind-
ing sites, although on average only three GABA molecules
need to bind agonist to gate the pore (7). Crucial amino acids
have been identified in these loops that interact with ligand
(8–15), and conformational changes have been revealed in
the binding site in response to agonist (16–19). It is certain
that at least some of these structural rearrangements trans-
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0006-3495/09/01/0045/11 $2.00duce the binding of agonist to the opening of the gate in
the ion pore. This gate is located some distance away from
the agonist-binding site, presumably near the middle of the
second transmembrane domain (20,21). Loop F (shown in
green in Fig. 1 A, with the amino acid sequence provided
in Fig. 1 B), owing to its location at the bottom of the binding
cleft (4), has been proposed to be a key transduction element
linking ligand binding to channel opening (22–24).
To date, there are three main approaches for inferring con-
formational rearrangements underlying receptor activation.
One technique employs the state dependence of accessibility
(25). In this method, cysteine residues are introduced at de-
fined locations and the accessibility to modification of the
free sulfhydryl side chains on these cysteines are compared
when the channels are in different kinetic states (open,
closed, or desensitized) (9,17,26). One complicating factor
of this somewhat indirect method is that the presence of
ligand itself, via steric hindrance of the accessibility reagent,
can impair modification. Thus, one is not necessarily looking
at conformational changes per se, but rather the ability of the
modifying reagent to reach its target cysteine. A second
method is structural resolution in combination with molecu-
lar modeling. The structural information has been derived
mainly from electron microscopy of the nACh receptor
(21,27,28) and x-ray crystallography of the acetylcholine-
binding protein (4), the extracellular domain of the nACh
receptor (29), and the recently crystallized prokaryotic mem-
ber of this cys-loop family (30). Issues to consider are that
the structures are static snapshots of the receptors in typically
unknown kinetic states (open versus closed) and the model-
ing is limited by our incomplete understanding of the com-
plex set of forces that determine structural stability and con-
formational dynamics. The third approach is site-directed
doi: 10.1016/j.bpj.2008.09.011
46 Khatri et al.FIGURE 1 Structures of the GABA receptor, ligands,
and fluorophore. (A) Structural model of the human r1
GABAC extracellular domain constructed by homology
with the AChBP. Two subunits comprising a single ago-
nist-binding site are shown. The six loops that form the
binding pocket are colored as follows: loop A, red; loop
B, yellow; loop C, purple; loop D, brown; loop E, blue;
loop F, green. The docked GABA molecule is shown in
a preferred orientation with the amino group (blue) proxi-
mate to loop C, and the carboxylic acid group (oxygens
in red) proximate to loop E. An expanded view of the
GABA molecule in the binding site is also shown. (B)
Aligned sequences of loop F for the GABAC receptor, three
GABAA receptor subunits, and the AChBP. The five bold
residues are the main amino acids investigated in this
study. (C) Structures of the ligands utilized and Alexa
546 maleimide (A5m).fluorescence spectroscopy, as employed here (16,18,31). In
this method, an environmentally sensitive fluorophore is
attached to cysteines introduced at defined positions in the
receptor. Changes in hydrophobicity around the fluorophore
produce measurable changes in fluorescence. Although this
method identifies regional structural rearrangements, some
caution must be used when interpreting these data. First,
the fluorophores detect changes in environmental hydropho-
bicity, and not necessarily movement of the domain (cyste-
ine) to which the fluorophore is attached. Another limitation
is the size of the fluorophore and, although tethered, its rota-
tional mobility. Still, this is a powerful new method that,
when coupled with an electrophysiological analysis, can
reveal insights into the dynamics of ion channel and receptor
activation mechanisms (16,18,31,32).
In this study, using a combination of two-electrode volt-
age clamp and site-directed fluorescence spectroscopy, we
tested the hypothesis that loop F in the agonist-binding site
is a key element along the pathway coupling agonist bind-
ing to channel opening. Although we document structural
rearrangements in this region, our data indicate that these
rearrangements signal the presence of ligand, and not the
degree of activation.
MATERIALS AND METHODS
cDNA and cRNA preparation
Site-directed mutagenesis was carried out with the use of standard polymer-
ase chain reaction techniques described previously (10). The fragments were
cloned into pGEMHE in the T7 orientation and the sequence was verified by
automated DNA sequencing. cDNA was prepared for wild-type and mutant
r1 subunits using a midi-prep kit (Promega, Madison, WI) and eluted with
RNase free water (Ambion, Austin, TX). Ten micrograms of cDNA were
Biophysical Journal 96(1) 45–55linearized by Nhe I digestion (NEB Labs, Ipswich, MA) which was then
used to prepare the cRNA. The Ambion T7 mMessage mMachine kit was
used to transcribe the cDNA into capped cRNA that was eluted with nucle-
ase free water (Ambion, Austin, TX).
Oocyte harvesting and cRNA injection
Female Xenopus laevis (Xenopus I, Dexter, MI) were anesthetized with 0.1%
MS-222 (Sigma Aldrich, St. Louis, MO). Oocytes were surgically removed
from the anesthetized frogs and washed with calcium-free OR2 (92.5 mM
NaCl, 2.5 mM KCl, 10 mM HEPES, and 1 mM MgCl2) at pH 7.5. This
procedure was approved by the Institutional Animal Care and Use Commit-
tee of the University of Texas Health Science Center at San Antonio. The
oocytes were defolliculated using 0.1–0.2% collagenase A (Roche Applied
Science, Indianapolis, IN) in calcium-free OR2 for 1.5–2 h at room temper-
ature. The oocytes were then washed and stored in ND96 (96 mM NaCl,
2 mMKCl, 1 mMMgCl2, 5 mMHEPES, and 1.8 mMCaCl2) with 5% horse
serum (Invitrogen, Carlsbad, CA), 25 mM sodium pyruvate (Sigma Aldrich,
St. Louis, MO) and 20 mg/L gentamicin (Invitrogen, Carlsbad, CA) at
pH 7.5. Stage VI oocytes were sorted and stored at 16C before injection
of cRNA. Microinjection needles were prepared on a Sutter P-97 horizontal
puller (Sutter Instrument, Novato, CA) and a Nanoject II microinjection
system (Drummond Scientific, Broomall, PA) was used to inject the
cRNA into the oocytes. The injected oocytes were incubated at 16C for
3–4 days before labeling and recording.
Fluorophore labeling
Alexa Fluor 546 C5 maleimide (A5m; Molecular Probes, Eugene, OR) was
reconstituted with dimethyl sulfoxide to a 5 mM stock solution and stored at
20C until needed. Oocytes were rinsed three times with OR2 before la-
beling. The A5m stock solution was diluted to 20 mM in OR2 at pH 7.2
before use. Oocytes were labeled for 30 min while they were slowly shaken
at room temperature. After labeling, the oocytes were washed in OR2
(pH 7.5) twice and placed in the recording chamber. It should be mentioned
that all five subunits carry the cysteine mutation, so there is a potential for
pentameric labeling by A5m. Given that this is a presumably symmetric
homomeric receptor, we assume that all five cysteines have an equal like-
lihood of being labeled. Although experiments demonstrated that our
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etry of the labeling.
Site-speciﬁc ﬂuorescence spectroscopy
A two-electrode voltage clampwas used tomeasure the expression level of the
injected oocytes. The labeled oocytes were placed in a unique recording
chamber so that both fluorescence and current could be measured simulta-
neously (16). The chamber consists of two sections separated by a 0.8 mm
aperture on which the oocyte sits. The oocyte was impaled for two-electrode
voltage clamp in the top chamber, and agonist was applied in the lower cham-
ber. An Axiovert 200 (Zeiss, Jena, Germany) was used to image the fluores-
cence from the bottom of the chamber. In this way, currents and fluorescence
were recorded from the same subpopulation of receptors in the lower chamber.
The oocyte was clamped at40 mVwith a GeneClamp 500 (Axon Instru-
ments, Foster City, CA) to measure the ligand-induced currents. A 90 W
halogen bulb was used as the light source in the DeltaRAM monochromator
(PTI, Birmingham, NJ). Light (546 nm) was passed into the microscope via
a liquid light guide. The microscope holds dichroic (HQ570LP) and
emission (HQ610/75m) filters (Chroma Technology, Brattleboro, VT) for
fluorescence detection. The fluorescence signal was detected by a photomul-
tiplier tube (R1527P Hamamatsu Photonics, Bridgewater, NJ) housed in the
PTI model 814 and mounted on the side port of the microscope. The data
were digitized at 20 Hz with an ITC-16 (InstruTECH, Port Washington,
NY) connected to a Macintosh computer (Apple Computer, Cupertino,
CA). The fluorescence and current data were recorded and analyzed by
IGOR Pro (WaveMetrics, Lake Oswego, OR). The dose-dependent relation
for the agonist was fitted with the following equation:
I ¼ Imax
1 þ ðEC50=½AÞn (1)
where I is the current generated by a specific concentration of the agonist,
[A]; Imax is the maximum current; EC50 is the concentration of [A] that is
required to obtain 50% of the Imax; and n is the Hill coefficient (slope). Stu-
dent’s t-test allowed us to compare the EC50 values for the mutants (L216C,
K217C, T218, S223C, I229C, D219C, S225C, and L228C) before and after
labeling with A5m, as well as DF and DI values between the different
ligands. We used the following ligand concentrations: trans-aminocrotonic
acid (TACA), 500 mM; GABA, 200 mM (for the I229C mutant we used
1000mM); imidazole-4-acetic acid (I4AA), 1000mM; isoguvacine, 1000mM;
and 3-aminopropylphosphonic acid (3-APA), 500 mM. In the case of
agonists, these were saturating concentrations for channel activation (cur-
rents) determined from dose-response relations fit with Eq. 1. For the antag-
onist 3-APA, 500 mM gives complete block of receptor activation at lower
agonist concentrations. The only exception was for L216C and I4AA, where
1000 mM was subsaturating and produced a current that was 68% of the
maximum as determined from extrapolation of the dose-response relation.
All agonists and antagonists were purchased from Sigma Aldrich.
Homology modeling and docking
A structural model was created for the amino terminal domain of the r1
subunit based on the AChBP crystal structure (PDB number 1i9b) (4)
with the use of ICM Pro and Homology (Molsoft, San Diego, CA). The
amino acid sequence was first aligned for the r1 subunit and the AChBP.
Next, the amino terminal domain of the r1 subunit was threaded onto
the AChBP crystal structure. Each subunit was modeled individually and
regularized, correcting for the lack of hydrogens in the PDB structure.
The modeled subunits also underwent a local energy minimization before
being grouped as one object. After grouping, the side chains of the amino
acids were energy-minimized and optimized to the lowest energy level to
generate a model for ligand docking.
Toset up theGABAdockingproject,wefirst identifiedpotential ligand-bind-
ing sites. The interface for subunits A and E were chosen to dock GABA. A li-
gand probe was placed behind loop C and a box (24.0  26.4  24.3 A˚) wasplaced around this potential ligand-binding area. Receptormapswere generated
before GABA was docked into the rigid receptor model. GABA was docked
into a rigid structure and generated 30 potential conformations. The orientation
of GABA shown was the lowest energy of all the potential orientations.
RESULTS
Mutations and labeling have minor effects
on channel activation
Residues in loop F of the r1 GABA receptor subunit were
mutated to cysteine, one at a time, to provide a free sulfhy-
dryl group to bind A5m. A previous cursory substituted
cysteine accessibility method (SCAM) analysis of loop
F demonstrated minor changes in receptor sensitivity with
these cysteine mutations (10). Here, we extended this analy-
sis to determine whether the attachment of A5m compro-
mises receptor function. All available evidence indicates
that the only available cysteine for fluorophore attachment
is the cysteine introduced by mutagenesis (9,10). We also
made the assumption that shifts in GABA sensitivity with
incubation in A5m confirm that the cysteine residue is acces-
sible and labeled by the fluorophore. Fig. 2 A shows repre-
sentative currents from the K217C mutant before (top traces)
and after (bottom traces) incubation in 20 mM A5m. The
graph in Fig. 2 B is a plot of the dose-response relation
(with and without A5m labeling) for the wild-type receptor
and two representative mutants in loop F. The top section
of Table 1 presents the EC50 values for the five loop F
FIGURE 2 Dose-response relations of cysteine mutants before and after
labeling with the fluorophore, A5m. (A) GABA-activated currents before
(top) and after (bottom) labeling with A5m in the K217C mutant. (B)
Dose-response relations for the wild-type receptor and two cysteine mutants
before and after A5m labeling.Biophysical Journal 96(1) 45–55
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Receptor
Unlabeled A5m Labeled
EC50 (mM) Hill coefficient n EC50(mM) Hill coefficient n
WT 0.985 0.04 2.785 0.21 3 1.045 0.04 3.505 1.00 3
L216C* 0.585 0.05 1.505 0.14 4 4.265 0.11 3.875 0.27 4
K217C* 1.095 0.05 1.725 0.27 3 1.485 0.11 2.145 0.15 5
T218C* 1.605 0.11 2.105 0.17 3 0.855 0.06 1.805 0.06 5
S223C* 3.395 0.05 1.825 0.03 3 2.345 0.31 1.625 0.08 5
I229C* 3.995 0.43 1.975 0.04 3 2.975 0.07 2.045 0.07 4
D219C* 3.495 0.25 1.245 0.01 3 5.025 0.38 1.385 0.01 3
S225C 0.415 0.02 2.135 0.10 3 0.465 0.02 2.135 0.03 3
L228C* 0.185 0.02 2.375 0.60 3 0.415 0.004 1.975 0.5 3
*Statistically significant difference between unlabeled and A5m labeled (p < 0.05).residues that are central to this study (L216C, K217C, T218C,
S223C, and I229C) plus three others to be discussed subse-
quently. Although therewas a slight shift inGABAsensitivity
with mutagenesis and labeling, the effect was surprisingly
modest given the cysteine substitution and the attached fluo-
rophore. Nevertheless, these data confirm what a previous
SCAM analysis of loop F suggested in the GABAC (10) and
GABAA receptors (22). Although the majority of loop F is
accessible tomodification, the impact of the cysteine substitu-
tions and sulfhydryl modifications on agonist-mediated
activation are modest, and this observation is relevant for
a consideration of the role of loop F in the activation process.
Most residues in loop F demonstrate
a GABA-mediated change in ﬂuorescence
Oocytes expressing the mutant GABA receptors were
labeled with A5m as described in Materials and Methodsand then placed in the recording chamber for the simulta-
neous measurement of GABA-mediated changes in current
(DI) and fluorescence (DF). This fluorophore can detect
changes in the hydrophobicity of the surrounding environ-
ment via changes in its fluorescence intensity. Fig. 3 shows
the putative structure of loop F (for orientation, see Fig. 1 A)
with representative fluorescence changes in response to a
saturating concentration of GABA. Although background
fluorescence was detected in labeled oocytes expressing
either wild-type GABA receptors or no GABA receptors at
all, this would be expected since free and accessible sulfhy-
dryl groups must certainly exist on endogenous oocyte
membrane proteins and would therefore be labeled by the
A5m. No change of fluorescence in response to GABA
application was observed for oocytes expressing either
wild-type receptors or no GABA receptors at all (noninjected
oocytes).FIGURE 3 Fluorescence changes in loop F. Each
residue in loop F was mutated to cysteine, one at a time,
labeled with A5m, and then exposed to a saturating concen-
tration of GABA. The positions that do not show a change
in fluorescence in response to GABA are shown in gray.
Biophysical Journal 96(1) 45–55
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(increase versus decrease) varied at different locations along
loop F. An increase in fluorescence for A5m indicates that
the environment surrounding the attached fluorophore is
increasing in hydrophobicity, whereas a decrease in fluores-
cence indicates a decrease in hydrophobicity. We interpret
these changes in fluorescence as structural changes around
the fluorophore. In a previous study using this approach,
we considered the possibility that the change in fluorescence
could result from quenching of the fluorophore by the ligand
itself. The potential problem of quenching was previously
refuted in this same system in other regions of the binding
pocket (16). In the study presented here, this potential prob-
lem is even less likely because loop F is quite distant from
the ligand molecule (Fig. 1).
Of the 14 residues analyzed, 11 showed a fluorescence
change when GABA was applied. For three of the loop F
residues (D219C, S225C, and L228C), however, there was
no observed change in fluorescence in response to GABA
application. This raises the question as to whether these
positions were accessible by A5m. To address this issue,
dose-response relations were measured before and after
incubation in A5m. In the case of D219C and L228C, label-
ing with A5m imparted a significant change in the GABA
sensitivity, suggesting that these positions are indeed acces-
sible and labeled (Table 1). In contrast, the agonist sensitivity
of S225C was the same before and after A5m exposure
(Table 1). At this time, we are unable to confirm whether
this is because the cysteine was not accessible to A5m, or
there was labeling but no change in GABA sensitivity.
We will delay a detailed consideration of the implications
of these DF values until the Discussion; however, a few
features of these data are worth pointing out here. First, a
majority of the positions demonstrate aDF, indicating that all
of loop F is undergoing an environmental change. Second,
there are some interesting features in the pattern of these
changes. Note that there can be changes in fluorescence of
opposite sign at adjacent residues (L216C, K217C, and
T218C). This difference in DF at adjacent positions confirms
that we are likely observing a structural rearrangement of (or
around) loop F rather then a direct response (quenching) im-
parted by the presence of the GABA molecule itself. Also
note that at the bend of loop F, namely S223C–F227C, the
DF decreased, suggesting that upon activation the environ-
ment around this particular section becomes more exposed
to the aqueous phase. Molecular-dynamics studies have
also shown that this region in nACh receptors moves into
a more aqueous environment upon activation (33).
Comparison of GABA-mediated changes in
ﬂuorescence and current in response to agonists,
partial agonists, and competitive antagonists
If loop F were indeed a structural element coupling agonist
binding to the opening of the pore, then, in its simplestform, this hypothesis would predict a correlation between
the change in fluorescence and the degree of receptor activa-
tion. To test this hypothesis, we employed partial agonists
and competitive antagonists. Partial agonists bind to the
same site as that of GABA, but do not fully activate the
receptor. Competitive antagonists are an extreme example
of a partial agonist in that they also bind to the same site,
but do not activate the receptor at all. This approach will
enable us to examine receptors under conditions with compa-
rable binding-site occupancy but exhibit a range of maximal
receptor activations.
For this analysis we focused on the five positions in loop F
that gave robust, consistent changes in current and fluores-
cence, and produced only modest shifts in sensitivity with
cysteine mutagenesis and A5m labeling. These five positions
are distributed throughout loop F, and we therefore assume
that the fluorescence changes at these positions reflect struc-
tural rearrangements of (or around) this entire domain. Fig. 4
shows representativeDF and DI values in response to GABA
and/or TACA (full agonists), I4AA and/or isoguvacine
(partial agonists), and 3-APA (competitive antagonist), all
at saturating concentrations (excluding I4AA for L216C,
as mentioned in Materials and Methods). We also show
data for L166C, a residue in loop E of the binding site
(Fig. 1 A), and this will be discussed subsequently. Bar
graphs are provided that plot the DF and DI for each ligand
normalized to that of GABA. First, note that comparison of
the relative magnitudes of the agonist-mediated currents
(black bars, normalized to GABA) varies for a given agonist
on the different mutants. For example, the partial agonist
isoguvacine yielded currents that were 18%, 35%, and
65% that of GABA for L216C, K217C, and T218C, respec-
tively. For comparison, the wild-type efficacies were GABA,
1.0; I4AA, 0.035 0.00; and isoguvacine, 0.465 0.01 (n ¼
5). Thus, the substitutions can alter the efficacy profile, and
this is not unexpected since loop F is a structural component
of the binding pocket. Still, in all cases, GABA or TACA is
the most potent agonist, 3-APA is a competitive antagonist,
and the other ligands fall somewhere in between these two ex-
tremes in terms of activation and are therefore partial agonists.
A comparison of the I4AA data typifies the obvious lack
of correlation between DF and DI. For L216C, K217C,
T218C, and S223C, this partial agonist was of low efficacy,
as revealed by the small current amplitudes, yet the DF was
indistinguishable from that of GABA (p < 0.05). Another
example of this lack of correlation is provided by 3-APA,
the competitive antagonist. In all cases, no currents were eli-
cited by 3-APA, although the DF values for L216C, K217C,
and T218C were similar to that induced by the partial agonist
isoguvacine. In the case of I229C, the DF for the competitive
antagonist, 3-APA, was indistinguishable from that of the
full agonist, GABA (p > 0.05). Although the normalized
DF and DI values for the partial agonist isoguvacine were
not quantitatively correlated to each other (e.g., constant
ratio), they did show intermediate normalized values for allBiophysical Journal 96(1) 45–55
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fluorescence for a series of ligands. In all six
panels, the top traces show the currents and
the lower traces show the concomitant changes
in fluorescence. GABA and TACA are full
agonists, 3-APA is an antagonist, and I4AA
and isoguvacine are partial agonists. Five loop
F mutants, plus one mutation in loop E
(L166C), are shown. The bar graphs plot the
amplitude of the current (solid) and fluores-
cence (gray) normalized to that of GABA.
*This was a subsaturating I4AA concentration,
but note that the fluorescence is indistinguish-
able from that of a saturating concentration of
the full agonist, GABA.five loop F mutants. As described below, however, an exam-
ination of the entire array of mutants and ligands indicated
that, as a whole, the DF and DI values were not correlated.
Fig. 5 is a scatter plot of the current versus fluorescence for
each mutant and each agonist normalized to that for GABA.
Each mutant is represented by a separate symbol, with
the color indicating the particular agonist or antagonist.
Although there is no a priori reason to assume a slope of
FIGURE 5 Relation between the change in current and change in fluores-
cence for the five loop F mutants. The amplitudes of the change in current
and fluorescence were normalized to that of GABA and plotted against
each other. The data seem to cluster by the particular agonist rather than
the degree of activation.
Biophysical Journal 96(1) 45–55one in this relation, if the DF observed in loop F upon acti-
vation represented the transduction between the binding of
GABA and the opening of the pore (for example), some
correlation would be evident. What is observed, however,
is a clustering of the DF values based on the particular ligand
but irrespective of the level of activation. It is worth noting
from Fig. 5 that the competitive antagonist 3-APA spans
the complete range of fluorescence changes, but in all cases
generates no current. This is different from the ligands that
open the channel and span a large range in their DI but
a very limited range in their DF.
To put these observations into perspective, data from the
mutant L166C in loop E are shown in Fig. 4. Previous
work on this mutation demonstrated fluorescence changes
in response to GABA that are actually opposite in sign to
that of the competitive antagonist (16). That earlier study
concluded that structural rearrangements associated with
this position reflect the degree of activation, at least for
a full agonist (GABA) and a competitive antagonist (3-
amino-propyl-(p-methyl)-phosphinic acid, or 3-APMPA).
Fig. 4 (lower right panel) shows this correlation extended
to other ligands. Whereas the full agonists GABA and
TACA mediate comparable DF and DI values, 3-APA and
isoguvacine produce no currents and have DF values oppo-
site in sign to that of the full agonists. (In the case of the
L166C mutation, isoguvacine has been converted from a par-
tial agonist to an antagonist.) The observation that agonists
GABA Receptor Structural Rearrangements 51and antagonists produce DF values of opposite sign suggests
that the structural rearrangements involving L166C are
correlated with receptor activation.
Relation between the dose dependence
of the current and DF
A previous study of the r1 GABA receptor demonstrated
that radiolabeled agonist binding occurred at lower concen-
trations than receptor activation (34). Thus, ligand binding
is detected at GABA concentrations where there is essen-
tially no channel opening. This is a consequence of the
activationmechanism of the r1GABA receptor, where amin-
imum of three molecules of GABA are required to open the
pore (7). If the structural rearrangements in loop F observed
here are associated with GABA binding rather than receptor
activation, we would predict that the dose dependence of DF,
like that of ligand binding, occurs at lower agonist concentra-
tions than channel opening. This approach of comparing the
dose dependence of fluorescence and activation has also
been employed in the nACh receptor at a position in the
a-d subunit interface to differentiate rearrangements associ-
ated with agonist binding versus latter steps in the activation
process (35). The analysis requires the collection of DFs at
low GABA concentrations, a difficult endeavor given the
amplitude of our signals. We were successful, however, in
constructing simultaneous and complete dose-response rela-
tions for DF and I in the K217C mutant. The results from
these experiments are shown in Fig. 6. At this particular
FIGURE 6 Dose dependence of current and DF at K217C. DF and I were
measured simultaneously at a range of GABA concentrations. These data,
normalized to their respective maxima, were then plotted as a function of
GABA concentration. Note that DF occurred at GABA concentrations lower
than that of channel opening. The Hill equation was fitted to these data,
yielding EC50 values of 0.905 0.64 and 5.345 1.25, and Hill coefficients
of 1.055 0.085 and 1.565 0.16 (n ¼ 13) for DF and I, respectively.position, the dose dependence of DF occurred at lower
GABA concentrations than the concomitant activation, with
EC50 values of 0.905 0.64 and 5.345 1.25 (n¼ 13), respec-
tively. These data are consistent with our hypothesis that the
structural rearrangements in loop F signal ligand binding.
Contrast this with data obtained in a previous study that
looked at structural rearrangements at L166C, a position in
loop E of the amino terminal domain (16). In that case, the
dose dependence of DF and I were essentially superimpos-
able, consistent with rearrangements of loop E being more
closely correlated with receptor activation.
DISCUSSION
The initial event in GABA receptor activation is the specific
binding of agonist to its binding site located at subunit inter-
faces. Structure-function analyses, mainly employing site-
directed mutagenesis, have identified the key residues that
interact with ligand (8–15). These studies, along with the
crystallization of AChBP, produced the six-loop model for
the GABA-binding pocket considered in the Introduction
(4). More recently, and in the study presented here, efforts
have been made to elucidate the dynamics, or conformational
rearrangements, that occur in the agonist-binding site in re-
sponse to ligand binding, as well as the structures responsible
for transducing this binding event to the gate, presumably
formed by the transmembrane domains and near the center
of the lipid bilayer (16–19). In this study, we focused our
efforts on loop F, a candidate for a domain that couples
ligand binding to channel opening in this cys loop family
of receptors. Before proceeding with our working hypothe-
sis, however, we should consider the assumptions and limi-
tations of the experimental approach.
Assumptions and limitations
We employed a combination of electrophysiology and site-
directed fluorescence spectroscopy to specifically address
the role of loop F in activation of the homomeric r1 GABAC
receptor. We made the working assumption that if structural
rearrangements in loop F are crucial for triggering activation,
these structural rearrangements should correlate with chan-
nel opening. We make the simplifying assumption that if
two different ligands, when bound, produce similar changes
in hydrophobicity, then the conformation of that region will
likely be similar in the two cases. It is possible, however, that
two very different and even opposite structural rearrange-
ments could generate two similar fluorescence signals
because the fluorophore moves into similar hydrophobic
environments. We also reasoned that the conformation of
the agonist-binding site would depend on the particular
ligand bound. This reasoning was based on structural studies
of glutamate receptors crystallized in the presence of ago-
nists, partial agonists, and antagonists that concluded that
the binding site adopts a conformation that correlates withBiophysical Journal 96(1) 45–55
52 Khatri et al.the degree of activation (36). Fluorescence spectroscopy
studies on GABA receptors have also identified putative
structural differences depending on whether agonists or
antagonists are bound (16,18). In addition, studies in the gly-
cine receptor using a similar approach as ours demonstrated
distinct DF values in the external portion of the second trans-
membrane domain (M2) with the binding of agonists, partial
agonists, and antagonists. Evidence indicates that this partic-
ular segment of the M2 domain may be important in the
coupling between agonist binding and channel opening (37).
Finally, we have assumed that partial agonists produce
a low maximum open probability compared to full agonists,
owing to differences in the closed-to-open equilibrium (38).
In this case, partial agonists stabilize the agonist-bound
closed state relative to full agonists that tend to favor the
agonist-bound open state. More recently, detailed single-
channel analyses of the nACh and glycine receptors sug-
gested that differences in the relative agonist efficacy occur
at a state between agonist binding and channel opening
(39). In either situation, the kinetic states visited by the
receptor are the same for partial or full agonists, although
the relative occupancies vary. In this case, if loop F were
a transduction element undergoing a structural change
upon activation, the observed steady-state fluorescence
would represent the average fluorescence as the receptor flips
back and forth between the activated and nonactivated
positions (the simplest case). In this scenario, a correlation
between the level of activation and the change in fluores-
cence would still be predicted since the steady-state fluores-
cence would be weighted by the relative occupancies of the
two states.
Regarding limitations, our fluorescence approach does not
allow us to derive the coordinates or magnitudes of structural
movements, or even to determine whether loop F is moving
(as opposed to the environment surrounding loop F). It does,
however, report the degree of change in hydrophobicity sur-
rounding the fluorophore. And lastly, the fluorescence being
detected is at the fluorophore that is actually tethered to loop
F through a roughly 15 A˚ linker.
The role of loop F
Several generalities regarding loop F were considered when
we initiated this study. We will first consider the structural
literature, followed by functional data. Structural resolution
of the Lymnaea stagnalis AChBP loop F revealed a weakly
resolved ‘‘unusual’’ conformation that is now considered
a random coil (4). Structural resolution of the AChBP from
Aplysia californica in complex with a series of agonists
and antagonists indicates that loop F, along with loop C
(Fig. 1 A), undergoes the largest rearrangement of any struc-
ture in the amino terminal domain (40). When compared
with the unbound structure, and particularly relevant to our
work, it appears that these conformational changes in loop
F occur in response to agonists as well as antagonists (40).
Biophysical Journal 96(1) 45–55In terms of the refined 4 A˚ structure of the full-length
Torpedo marmorata, there is little mention of loop F except
to say that it does not extend down to the membrane-spanning
domains (28). In contrast, hydrophobic photolabeling of the
nACh receptor has indicated that loop F moves to a more
hydrophobic environment, suggesting that this domain may
make contact with the membrane surface (41).
Previous studies in which GABA was docked into the ag-
onist-binding cleft of a structural model for the r1 GABAC
receptor determined by homology with the Lymnaea AChBP
revealed a series of possible orientations, all of which place
loop F quite distant (5 A˚) from the bound agonist molecule
(42,43). Molecular-dynamics simulations in a structural
model of the nACh receptor indicate a slight outward rota-
tion of loop F and the removal of electrostatic contacts
with the neighboring subunit during receptor activation
(33). And finally, a recent dynamic analysis of the nACh
receptor study concluded that loop F plays a role in local
dynamics at the subunit interface and is likely involved in
regulating binding affinity, but is probably not important in
global channel motions (44).
Regarding functional information on the role of loop F
in cys loop receptor activation, a SCAM analysis of loop F
in the r1 GABAC receptor (10) demonstrated three points
worth considering here. First, the cysteine mutations them-
selves (except for one position, Q226C) produced only
very modest effects on receptor sensitivity. Second, nearly
all the residues were accessible by the hydrophilic reagent
[2-(trimethylammonium)ethyl]methanethiosulfonate bromide
(MTSET) in both the open and the closed state. And third,
the modifications by MTSET were not protected by the pres-
ence of agonist or antagonist. Taken together, these data sug-
gest that residues in loop F probably do not interact with the
bound ligand. Also, any structural changes imparted by the
agonist do not bury the cysteine side chains in a hydrophobic,
inaccessible environment. To summarize the structural and
functional results, there is no definitive evidence that the
rearrangements postulated to occur in loop F in response to
agonist serve as a trigger for the conformational wave that
leads to the opening of the pore.
When we examined five representative positions through-
out loop F, with a series of agonists that went from full
activation to complete antagonism, we observed no clear
correlation between the magnitude of the current and fluores-
cence. Most notably, at four of the five positions, fluores-
cence changes were indistinguishable, although currents
were either very small (I4AA, partial agonists) or absent
(3-APA, antagonist). This led us to conclude that even
though loop F may be rearranging in response to the
presence of ligand, this domain is probably not along the
transduction pathway leading to channel opening. Given
this conclusion, it is interesting that some of the loop F cys-
teine mutations themselves altered the relative efficacy of the
ligands. At face value, this observation seems to support
a role of this domain in channel activation. However, the
GABA Receptor Structural Rearrangements 53inherent coupling between ligand binding and channel acti-
vation makes it a dangerous prospect to assign specific ac-
tions of a mutation on one versus the other (45,46). It is worth
mentioning that a SCAM analysis of loop F in the related
5-HT3 receptor also concluded that structural changes in this
region depend on the presence of ligand, although not neces-
sarily on whether the ligand is an agonist or antagonist (24).
Working hypothesis
GABA and 3-APA have comparable structures (Fig. 1 C),
and 3-APA displays all the hallmarks of a classic competitive
antagonist for GABA-mediated activation (47,48). It there-
fore stands to reason that the interactions between these li-
gands and the components of the binding pocket responsible
for their affinities are similar. It is generally accepted that the
structural rearrangements that occur upon agonist binding, in
an ‘‘induced-fit’’ mechanism, close down around the ligand
and trap it in the pocket. Our work on the r1 GABA receptor
using the single oocyte binding technique has confirmed that
channel opening locks GABA into the binding pocket (34).
Although the interactions responsible for the affinities of
GABA and 3-APA are likely similar, some key differences
must certainly exist in the bound structures since GABA
opens the pore but 3-APA does not. The structures of the
full agonist, GABA, and the competitive antagonist, 3-
APA, are identical at the amino end but very different at
the carboxylic acid end, where 3-APA has a substituted
phosphonic group (Fig. 1 C). If the orientation of GABA
in the binding pocket is correct (Fig. 1 A), the amino group
of the ligand (blue) would be positioned near loop C with
the opposite end (oxygens indicated in red) pointed at loop
E (light blue). This position and orientation agree with a pre-
vious study that placed the carboxylic acid group of GABA
near arginine 158 on the E loop (43,49).
Loop C is a prominent protrusion in the binding pocket
(Fig. 1 A) that extends across neighboring subunits (4).
Upon agonist binding, loop C presumably closes the ligand-
binding pocket by an inward movement (twist and rotation)
toward its parent subunit (21,28,33,50–53). Loop C also con-
tains residues that are crucial for ligand binding, including
a well-conserved tyrosine that has been postulated (8,54) to
play a direct role in stabilizing the agonist molecule, perhaps
via p electrons associated with the aromatic ring (55,56). If
the docked location of GABA depicted in Fig. 1 A
is correct, then loop C may not distinguish agonist versus
antagonist since it is proximate to the similar amino ends of
the ligand. Note that loop F actually connects loops A and
C, and loop A has also been postulated to be an important de-
terminant for receptor affinity (10,13). Based on our data,
and by virtue of the close association and mechanical link
to loop C, we propose that loop F is part of the machinery
that locks ligand into the binding site. In support of this, there
are naturally occurringmutations in loop F of the nACh 3 sub-
unit that appear to alter the microscopic binding affinity forACh (57). The rearrangement we observe about loop F may
simply be because it is a pivot point, or hinge, between loops
A andC. It is alsoworthmentioning that loopF connects loops
A and C of the neighboring binding site (Fig. 1 A). Therefore,
loop F could be in a position to transduce any allosteric cou-
pling between adjacent binding sites (58). In support of this,
loop F of the g2 subunit seems to transduce allosteric modula-
tion by benzodiazepines ina1b2g2GABA receptors (59–61).
We have shown previously (16), and extended the analysis
here, that structural rearrangements in loop E (L166C) seem
to reflect the degree of activation or antagonism since very
different fluorescence changes (opposite in sign) were ob-
served between ligands that activate and ligands that antag-
onize the receptor. A similar relation was demonstrated in
a study using site-directed fluorescence spectroscopy in
a1b2 GABAA receptors (18). Of interest, loop E is adjacent
in sequence to the amino terminal cys-cys loop that has been
proposed to interact with the linker between TM2 and TM3
via a salt bridge network, thereby leading to channel opening
(23,62–68). More specifically, isomerization of a conserved
proline in the TM2-TM3 loop from the trans to cis confor-
mation may couple the amino terminal domain structural re-
arrangements to the rearrangement of TM2 that opens the
pore (69). Based on all available evidence, we are turning
our attention to loop E as a structure that may sense the pres-
ence of agonist and initiate the conformational wave toward
the gate to open the ion channel.
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